Provided by Tiger Trade Technology Pte. Ltd.

Kazia Therapeutics Limited

10.39
-0.4700-4.33%
Post-market: 10.390.00000.00%16:04 EDT
Volume:169.38K
Turnover:1.79M
Market Cap:145.53M
PE:-1.52
High:11.00
Open:10.89
Low:10.38
Close:10.86
52wk High:17.40
52wk Low:4.86
Shares:14.01M
Float Shares:11.66M
Volume Ratio:0.47
T/O Rate:1.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.8190
EPS(LYR):-12.3849
ROE:-106.90%
ROA:-25.70%
PB:4.40
PE(LYR):-0.84

Loading ...

Kazia Therapeutics files beneficial ownership statement for Chief Scientific Officer Sudha Rao

Reuters
·
May 20

Kazia Therapeutics publishes corporate overview outlining oncology pipeline and development plans

Reuters
·
Apr 28

Kazia Therapeutics appoints Sudha Rao as Chief Scientific Officer

TIPRANKS
·
Apr 15

Press Release: Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform

Dow Jones
·
Apr 15

BRIEF-Kazia Therapeutics Ltd - Buys Global Rights To Setdb1 Platform With $1.39 Million Upfront Payment

Reuters
·
Apr 14

Kazia Therapeutics Ltd - Buys Global Rights to Setdb1 Platform With $1.39 Mln Upfront Payment

THOMSON REUTERS
·
Apr 14

Kazia Therapeutics in-licenses SETDB1 platform from QIMR Berghofer for $1.39 million upfront

Reuters
·
Apr 14

Kazia Therapeutics files Form 3 as David Cain named Director, CMC

Reuters
·
Apr 01

Kazia Therapeutics Ltd: on March 26, 2026, Bryce Carmine, the Current Chairman of the Board, Notified the Board of His Intent to Retire

THOMSON REUTERS
·
Apr 01

Kazia Therapeutics Director Steven R. S. Coffey Files Initial Beneficial Ownership Statement

Reuters
·
Mar 19

Kazia Therapeutics files initial beneficial ownership statement for CEO John E. Friend II

Reuters
·
Mar 19

Kazia Therapeutics’ Program Director Jeremy Simpson files initial beneficial ownership statement

Reuters
·
Mar 19

Kazia Therapeutics Limited VP of Finance and Controller Jeffrey Bonacorda files Form 3 initial beneficial ownership statement

Reuters
·
Mar 19

Kazia Therapeutics files Form 3 initial beneficial ownership statement for Director Robert F Apple

Reuters
·
Mar 19

BRIEF-Kazia Therapeutics Ltd Files For Offering Of Up To $200 Million Of American Depositary Shares Representing Ordinary Shares Or Warrants - SEC Filing

Reuters
·
Mar 18

Kazia Therapeutics Ltd Files for Offering of up to $200 Mln of American Depositary Shares Representing Ordinary Shares or Warrants - SEC Filing

THOMSON REUTERS
·
Mar 18

Kazia Therapeutics H1 net loss widens 20.08% to AUD 12.55 million

Reuters
·
Mar 16